REMDESIVIR
Remdesivir is a poison
A poison is a substance that can cause death or injury. Remdesivir is a drug that was documented to have a death rate of 53.1% in December 2019. It also has many other adverse effects such as kidney and liver damage.
Dictionary definition of poison:
Oxford Languages: A substance that is capable of causing the illness or death of a living organism when introduced or absorbed
Wikipedia: In biology, poisons are substances that can cause death, injury or harm to organs, tissues, cells, and DNA usually by chemical reactions or other activity on the molecular scale, when an organism is exposed to a sufficient quantity. In a metaphorical broader use of term it may refer to any thing deemed harmful.
dictionary.com: Poison, toxin, venom are terms for any substance that injures the heath or destroys life when absorbed into the system, especially of a higher animal.
Mirriam-Webster: The meaning of POISON is a substance that through its chemical action usually kills, injuries, or impairs an organism. Something destructive or harmful.
November 2019
Ebola Drug Trial Results - Remdesivir = 53.1% death rate
WHO & NIAID AWARE OF REMDESIVIR DEATH RATE
REPORTS PROVIDED BY LINK BELOW
27 November 2019 results from the National Institutes of Heath (NIH), the Democratic Republic of Congo (DRC), and the World Health Organisation (WHO) clinical trial of 4 experimental drugs to treat ebola were published.
The trial known as PALM was coordinated by WHO, and led and funded by the DRC’s National Institute for Biomedical Research and Ministry of Health, and the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health.
Following drug trials, remdesivir was rejected for use to treat ebola.
The report titled, Investigational Drugs Reduce risk of Death from Ebola Virus Disease” says:
“The study enrolled 681 people with Ebola virus disease between November 2018 and August 2019 at four Ebola treatment centers (ETCs) in the cities of Beni, Butembo, Katwa and Mangina.
The study was designed to compare mortality among patients who received one of three investigational Ebola drugs with that from a control group of patients who received the investigational monoclonal antibody cocktail ZMapp, developed by Mapp Biopharmaceutical, Inc.
The other therapies were mAb114, a single monoclonal antibody product developed for clinical use by NIAID’s Vaccine Research Center and the INRB and licensed to Ridgeback Biotherapeutics and Mapp Biopharmaceutical; REGN-EB3, a monoclonal antibody cocktail developed by Regeneron Pharmaceuticals, Inc.; and remdesivir, an antiviral drug developed by Gilead Sciences, Inc.
The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, also has provided support for the development of REGN-EB3, ZMapp and mAb114.
The final analysis included 673 participants. The trial began in November 2018 with randomized administration of remdesivir, mAb114 and ZMapp, and the protocol was amended to include REGN-EB3 in January 2019. As a result, the number of outcomes included in the ZMapp comparator group was slightly different for the initial arms (remdesivir and mAb114) relative to the number of outcomes in the ZMapp comparator group for REGN-EB3, based on time of enrollment.
Overall mortality was 50% (84/169) in all patients treated with ZMapp and 51% (79/154) in patients who received ZMapp during the time that REGN-EB3 was included as another trial arm.
Mortality rates were lower for mAb114 and REGN-EB3 compared to their respective ZMapp cohorts: 35% (61/174) of patients in the mAb114 treatment group and 34% (52/155) of patients in the REGN-EB3 group died by 28 days post-treatment.
The mortality rate in the remdesivir treatment group, 53% (93/175), was similar to ZMapp.”
2020 Covid Drug Trial - Remdesivir
On 21 February 2020 a new drug trial was commenced soley to trial remdesivir for the treatment of covid. 1062 patients underwent the trial, with 541 assigned to remdesivir and 521 to a placebo.
The trial was completed on 19 April 2020. Its report, titled “Remdesivir for the Treatment of Covid-19 - Final Report”, was published on 5 November 2020 - about 7 months after the trial was completed.
The purpose of the report was to assess “the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only”. Mortality was NOT an objective of the report, and therefore NOT reported.
The report states:
“BACKGROUND
Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious.
METHODS
We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19…
RESULTS
A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo)…. The Kaplan–Meier estimates of mortality were 6.7% with remdesivir … by day 15 and 11.4% with remdesivir… by day 29. Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%)…”
https://www.nejm.org/doi/full/10.1056/nejmoa2007764
Remdesivir Risk Versus Benefits Assessment
Drug Trials & Reports
Several reports undertaken into the adverse events of remdesivir conclude remdesivir causes a long list of adverse effects, the most critical being a 53% mortality rate. Remdesivir also causes kidney and liver injury.
In contrast, following a drug trial in February 2020, the only reported benefit remdesivir offered was a possible reduction in hospitalisation by 4 days. That report stated deaths occurred from remdesivir during the drug trial, however the mortality statistics were ignored, and mortality information kept from the world.
In consideration of risk versus benefit, it is incomprehensible any doctor would elect to inject a toxic poison that leads to 53% death, and/or kidney and liver injury where the only benefit may be a reduction of 4 days in hospital.
A poison is a substance that can cause death or injury. Remdesivir causes injury and death. Remdesivir is a poison.
Frank died with almost all of the published adverse effects of remdesivir, including death, multi organ failure, kidney failure, acute kidney injury, deep vein thrombosis, bruising and swelling to his face, body, lips and eyes.
Benefits of Remdesivir
BENEFIT: 4 days less in hospital
Following a drug trial for covid in February 2020, the only reported benefit of remdesivir is that it may reduce hospitalisation from 15 days to 11 days.
Mortality that resulted in the drug trail was ignored. As such, an entirely false representation of remdesivir was issued to the world.
In October 2020 The World Health Organisation (WHO) said remdesivir had “little or no effect in preventing death from COVID-19 or reducing time in hospital.”
Adverse Effects of Remdesivir
ADVERSE EFFECTS: Death, multi-organ failure, liver failure, kidney injury, +++++
The US National Institutes of Health (NIH) National Library of Medicine provides several remdesivir drug trial reports on its website. Links to the referenced reports are provided below.
On 22 May 2020 Drugs In Context (DIC) published a report titled“The journey of remdesivir: from Ebola to COVID-19”. The report was completed on 14 April 2020. The report outlines results of four drugs trialled to treat ebola. Remdesivir resulted in the highest death rate of the four drugs, with a death rate of 53.1%.
Page 4 the report states, “At day 28, mortality rates were: remdesivir (53.1%)”
NIAID was involved in, and provided funding for, the ebola drug trials, and as such was aware of the 53% dealth rate of remdesivir.
On 22 July 2020 Biomed Pharmacother published a report titled, “Safety profile of the antiviral drug remdesivir: An update”. The report provides a list of adverse events of remdesivir and the number of events (shown as a percentage below):
increased hepatic enzyme 25% (hepatitis or liver disease);
respiratory failure 4%;
pneumothorax 4% (collapsed lung - air leaks into the space between lungs and chest wall];
hypotension: 8% (high blood pressure);
atrial fibrillation 6% (irregular heart rate - heart’s upper chambers beat out of coordination with the lower chamber);
cardiac arrest 1%;
renal impairment 8% [kidneys lose ability to remove waste);
acute kidney injury 6%;
hematuria 4% (blood in urine); and
constipation, nausea, diarrhea, and gastroparesis.
The report also states, “Other adverse effects. Transient rise in serum amylase was reported in an Ebola-infected patient treated with remdesivir. Grein et al.’s study mentioned rash, multiple-organ-dysfunction syndrome, deep-vein thrombosis, delirium, septic shock, pyrexia as adverse events occurred in remdesivir recipients. Adverse events related to hematologic, circulatory, endocrine and other systems were also detected in the remdesivir group in the RCT in China.”
On 24 October 2020 Cureus published a report titled “Cardiac Adverse Events with Remdesivir in COVID 19 Infection”. The report states “Adverse effects are common with remdesivir, but few studies exist that focus on remdesivir and its effects on the cardiovascular system. Out of a study of 53 patients receiving remdesivir, 32 patients (60%) experienced adverse events during follow-up. These adverse events were increased hepatic enzymes, diarrhea, rash, renal impairment, and hypotension. Adverse events were more common for those on mechanical ventilation compared to those that were not.”
Queensland Health issued a document titled “Patient Information Remdesivir (Veklury)” which states remdesivir can cause swelling of the face, lips, tongue and other parts ofd the body, and severe skin rash including, itching and hives and nausea and vomiting.
Remdesivir: Drug Trial Report Links
The journey of remdesivir: from Ebola to Covid-19
Safety profile of the antiviral drug remdesivir: An update
Cardiac Adverse Events With Remdesivir in Covid-19
Queesland Health
Patient Information Remdesivir
Sources:
The journey ohttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250494/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373689/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682945/
Queensland Health Patient Information Remdesivir (Veklury). https://www.health.qld.gov.au/__data/assets/pdf_file/0025/1145149/remdesivir-patient-information.pdf
March 2020: Fauci reports benefit of remdesivir - 4 days less in hospital. No mention of death.
On 30 April 2020, Anthony Fauci, Director of the US National Institute of Allergy and Infections Diseases (NIAID) and Chief Medical Advisor to the President of the USA, promoted the outcomes of a remdesivir drug trial undertaken by the NIAID. In the media promotion, Fauci states remdesivir and/or a placebo were given to 1090+ individuals. He said,
“The primary endpoint was the time to recovery, namely the ability to to be discharged.…
The data shows that remdesivir has a clear cut significant positive effect in diminishing the time to recovery…. If you look at the time to recovery being shorter in the remdesivir arm, it was 11 days compared to 15 days.”
As such, the only purpose of the remdesivir trial was to access “hospital duration” and nothing else. A written report, states mortality occured, yet Fauci entirely refused to inform the world that death occurred.
On 30 April 2020 Fauci intentionally gave a false representation of remdesivir by excluding mortality information, and only reporting on reduced hospitalisation times. The reduced hospitalisation time was in October 2020 rejected by WHO who said there was no benefit in remdesivir.
Remdesivir must be considered in terms of risk versus benefit -
Risk: 53% chance of death - VERSUS - Benefit: 4 days less in hospital.
https://www.youtube.com/watch?v=92AICPrksFI
October 2020: Remdesivir gets FDA approval.
World Health Organisation fails to warn of death rates.
The World Health Organisation (WHO) was involved in the ebola trials in 2019, in which remdesivir resulted in a 53% mortality rate.
WHO undertook a drug trial from 22 March 2020 to 4 October 2020 of11,330 adults. The drugs trialled included remdesivir, hydroxychloroquine, lopinavir (fixed-dose combination with Ritonavir) and Interferon-β1a. The results were published in October 2020.
The report clearly shows deaths resulted with remdesivir, however WHO, refused to inform the world that remdesivir caused death and instead only made a message that remdesivir had not effect. On 22 October 2020, US News published WHO’s statement, which said,
“the drug had little or no effect in preventing death from COVID-19 or reducing time in hospital”.
WHO sent a deceptive message by only presenting one side of information - that remdesivir did not offer any benefits. It refused to inform that it resulted in death.
US NEWS ARTICLE
WORLD HEALTH ORGANISATION - INTERIM DRUG TRIAL RESULTS
The Guardian
US secures world stock of key Covid-19 drug remdesivir
1 July 2020
Sarah Boseley
https://www.theguardian.com/us-news/2020/jun/30/us-buys-up-world-stock-of-key-covid-19-drug
Online Guardian news article said, “The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.”
Anthony Fauci, as Chief Medical Advisor to the President of the USA, would have been involved in the decision making process to purchase the 500,000 doses of remdesivir for its American citizens.
That decision to purchase 500,000 doses of remdesivir was made after the ebola trials which documented a mortality rate of 53%.
The Guardian news in fact confirms remdesivir’s unacceptable drug trial results by saying, “The drug, which was trialled in the Ebola epidemic but failed to work as expected, is under patent to Gilead, which means no other company in wealthy countries can make it. The cost is around $3,200 per treatment of six doses, according to the US government statement.”
The Guardian refused to present all the facts - that remdesivir resulted in a 53% death rate in the ebola trials, and instead misled readers with a deceptive sentence that remdesivir “failed to work as expected” when in fact is caused death on a massive scale.
Further in the article Anthony Fauci said, “We are going in the wrong direction,” said Fauci. Last week the US saw a new daily record of 40,000 new coronavirus cases in one day. “I would not be surprised if we go up to 100,000 a day if this does not turn around,” he said. He could not provide an estimated death toll, but said: “It is going to be very disturbing, I guarantee you that.”
It is reasonable to conclude Anthony Fauci could “guarantee” the death toll would be “disturbing” because he was fully aware remdesivir causes death in 53% of cases, and the Trump administration purchased 500,000 doses for the American people, hence the high death toll experienced in hospitals.
CNBC
Gilead strikes deal to make remdesivir coronavirus treatment for 127 countries
Berkeley Lovelace Jr
13 May 2020
https://www.cnbc.com/2020/05/12/remdesivir-coronavirus-treatment-gilead-strikes-deal-to-make-drug-in-127-countries.html
In May 2020 CNBC reported that Gilead Sciences Inc, struck a massive deal to issue remdesivir to 127 countries plus the USA.
Gilead is the patent owner of the drug remdesivir. Remdesivir
was a drug rejected for use to treat ebola in November 2019 due to its mortality rate of 53%; and
is the drug that was selected in March 2020 to be the primary drug for use to treat covid-19 in hospitals.
The report also says, “The intravenous drug has helped shorten the recovery time of some hospitalized Covid-19 patients, new clinical trial data suggests. Without other proven treatments, physicians will likely be considering its use to treat the coronavirus.”
The news article refused to report on the documented death rates of remdesivir and presented a deceptive message of benefit from remdesivir.
Further, the report states, “The company has said it expects to produce more than 140,000 rounds of its 10-day treatment regimen by the end of this month and anticipates it can make 1 million rounds by the end of this year. Gilead said it will be able to produce “several million” rounds of its antiviral drug next year.”
On 2 February 2022 Mackenzie Bean of Becker’s Hospital Review reported “Gilead saw $5.6B in remdesivir sales last year.
Source: https://www.beckershospitalreview.com/pharmacy/gilead-saw-5-6b-in-remdesivir-sales-last-year.html.
The profits are disturbing in consideration that remdesivir carries massive risks including mortality, multi organ failure, kidney failure, liver damage, among many other adverse events. Remdesivir does not aid recovery of covid, as stated by WHO that said it did not reduce hospitalisation time or recovery.
The Guardian
Gilead donates Covid-19 drug remdesivir to Australia’s medical stockpile after US buys up supply
1 July 2020
Melissa L Davey
https://www.theguardian.com/australia-news/2020/jul/01/gilead-donates-covid-19-drug-remdesivir-to-australias-medical-stockpile-after-us-buys-up-supply
The Guardian reported in its online news article, “The US pharmaceutical giant Gilead has donated a supply of the antiviral medication remdesivir to Australia’s national medical stockpile, with the federal health minister, Greg Hunt, saying there will be enough of the drug to meet Covid-19 patient demand….
It followed news overnight that the US government bought virtually all of the global supply of remdesivir for the next three months. The drug has shown some promise in helping Covid-19 patients recover faster. However, it is not a cure. Remdesivir is the first drug approved by licensing authorities in the US to treat Covid-19, prompting the White House under US president Donald Trump to buy more than 500,000 doses, representing all of Gilead’s production for July and 90% of August and September.”
The news report once again refuses to inform readers of the high mortality rate of remdesivir.
The report further says, “Gilead announced its global price for remdesivir on June 29 as US$390 per vial. The Guardian reports that the cost will be US$3,200 for a six-day treatment, or A$4,607. The cost of production of remdesivir has been estimated to be less than US$1 per day or US$6 (A$8.64) for a six-day course of treatment.”
As such Gilead’s profit on a six-day course of treatment is $4,598.36 AUD.
Australian Government Stockpile of Remdesivir
An Australian government document published on 31 July 2020 provides critical information that Australia has a stockpile of the drug/poison remdesivir.
Remdesivir is the only hospital covid protocol used in hospital to treat covid. As such a drug that has 53% mortality rate was the only drug used in hospital to treat covid.
Frank went into hospital, was treated with remdesivir, and died.
Further, Frank was given remdesivir contrary to the criteria, which clearly states remdesivir is to be excluded for ventilated patients. The document states:
Exclusion Criteria
“Mechanical ventilation for longer than 48 hours at time of application”.
Frank was put on a ventilator at 2.22pm on 20 September 2021 and remainted on a ventilator until his death at 4.15pm on 7 October 2021.
Despite the fact Frank was continuously on a ventilator, the Canberra Hospital administered remdesivir contrary to these Australian government protocols.
MATTER OF CONCERN
This Australian government document states Australia has a STOCKPILE OF REMDESIVIR - a drug with a documented death rate of 53.1%.
Why does our government have a stockpile of poison, for the purpose of giving that poison to its citizens in hospitals?
On the basis that remdesivir has a documented 53% mortality rate, and it is the only hospital protocol in treating covid in hospitals, why are all deaths reported as covid death, when many are clearly remdesivir deaths.
Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-agreement-gilead-manufacture-remdesivir
Pfizer
Pfizer, one of the main manufacturers of the covid “vaccine”, announced it is producing the drug remdesivir on behalf of patent owner Gilead Sciences that has a documented death rate of 53.1%. The announcement said,
“NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for COVID-19. Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer’s McPherson, Kansas facility to manufacture and supply remdesivir for Gilead.
In March, Pfizer launched a five-point plan, which called on all members of the innovation ecosystem – from large pharmaceutical companies to the smallest of biotech companies, from government agencies to academic institutions – to commit to work together in addressing the dire COVID-19 crisis.
“From the beginning it was clear that no one company or innovation would be able to bring an end to the COVID-19 crisis. Pfizer’s agreement with Gilead is an excellent example of members of the innovation ecosystem working together to deliver medical solutions,” said Albert Bourla, Chairman and Chief Executive Officer. “Together, we are more powerful than alone. As one of the largest manufacturers of vaccines, biologics and sterile injectables, it is a privilege to offer our expertise and infrastructure to help fight this pandemic. In that spirit, we are pleased that Gilead is using our manufacturing capacity to help facilitate supply of this medicine to patients as quickly as possible.”
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Pfizer Disclosure Notice: The information contained in this release is as of August 7, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about Pfizer and Gilead’s multi-year agreement to manufacture and supply remdesivir, including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development; uncertainties regarding the commercial success of and the ability to realize the anticipated benefits of the manufacturing and supply agreement; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of remdesivir; uncertainties regarding the impact of COVID-19 on our business, operations and financial results; other business effects, including the effects of industry, market, economic, political or regulatory conditions; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results,” as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at http://www.sec.gov/ and www.pfizer.com.”
PFIZER MANUFACTURES VAX + REMDESIVIR
Pfizer, the first jab on the market, that was pushed through development and approval by former US President Donald Trump, now also manufacturers remdesivir on behalf of its French owner Gilead.
As such, Pfizer, that makes the jab for peoples throughout the world, now also makes the poison that has a death rate of 53.1%, for all the peoples in hospitals throughout the world.
Remdesivir was made the global covid hospital protocol, while all other drugs such as ivermectin were banned.
As such hospitals give people a poison that has a death rate of 53.1%, and when persons die, reports them as a “covid deaths”.
